FDA issues complete response letter for Bayer/J&J's Xarelto
This article was originally published in Scrip
Executive Summary
The US FDA has issued a complete response letter to Johnson & Johnson and Bayer for their oral, once-daily anticoagulant Xarelto (rivaroxaban).